{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0077385\nAge: 43\nGender: Female\nSample ID: P-0077385-T01-IM7\nGene Panel: IMPACT505\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 40.0%\n=============\nDNA Variants:\nARID1A c.4982_4985del (p.M1661Kfs*11) - in 21.00% of 592 reads\nATM c.7227A>C (p.E2409D) - in 21.00% of 594 reads\nATM c.7241A>C (p.Q2414P) - in 22.00% of 607 reads\nDNAJB1 c.774_792+13del (p.X258_splice) - in 26.00% of 648 reads\nERRFI1 c.511G>C (p.V171L) - in 10.00% of 693 reads\nMTOR c.7257A>C (p.E2419D) - in 23.00% of 451 reads\nCNA Data:\nSOX17 - High Level Amplification\nNCOA3 - High Level Amplification\nRECQL4 - High Level Amplification\nELOC - High Level Amplification\nAURKA - High Level Amplification\nLYN - High Level Amplification\nGNAS - High Level Amplification\nMYC - High Level Amplification\nPREX2 - High Level Amplification\nRAD21 - High Level Amplification\nPRDM14 - High Level Amplification\nAGO2 - High Level Amplification\nNBN - High Level Amplification\nRTEL1 - High Level Amplification\nStructural Variants:\nMAN1B1 - TRAF2 (DUPLICATION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Alpelisib (PI3K alpha inhibitor)\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": [\n      \"PIK3CA mutations (not identified in this profile, but MTOR mutation suggests PI3K/AKT/mTOR pathway activation)\",\n      \"MTOR c.7257A>C (p.E2419D)\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/alpelisib\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Everolimus (mTOR inhibitor)\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": [\n      \"MTOR c.7257A>C (p.E2419D)\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/everolimus\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"CDK4/6 inhibitors (e.g., Palbociclib, Ribociclib, Abemaciclib)\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": \"Amplifications in MYC and other cell cycle regulators suggest potential benefit from CDK4/6 inhibition\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/cdk4-6-inhibitors\"\n  },\n  \"Treatment 4\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"PARP inhibitors (e.g., Olaparib, Talazoparib)\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": [\n      \"ARID1A mutation (potential homologous recombination deficiency)\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/parp-inhibitors\"\n  }\n}"
}